Researchers at Nagoya University have engineered zinc oxide nanowires that grab hold of cancer's molecular fingerprints floating in the bloodstream—capturing 90% of cancer-linked extracellular vesicles in laboratory tests. The innovation promises to make cancer detection faster and far less invasive than traditional biopsies, requiring only a blood sample to reveal what a tumor is doing at the molecular level.
Extracellular vesicles, or EVs, are nanoscale particles that cells constantly shed into bodily fluids. They carry genetic and protein signatures of their origin, making them windows into disease states—if you can fish them out efficiently. Until now, isolating these invisible messengers from blood has been time-consuming and imprecise, requiring large sample volumes and lacking the specificity needed for accurate diagnosis. A liquid biopsy, as the technique is called, spares patients the burden of tissue biopsies, which involve cutting or needles. Yet it only works if you can reliably separate the disease signals from the noise.
Led by Takao Yasui, professor at Nagoya University's Graduate School of Engineering, a team spanning five Japanese research institutions solved the capture problem by conjugating antibodies to zinc oxide nanowires using a synthetic polymer called polyketone. The approach was deceptively simple yet crucial: they synthesized six variants of polyketone with different chain lengths and found that one version, pKNHS 4.2, stuck to the nanowires reliably while anchoring antibodies in a single step—eliminating the lengthy, nonspecific binding that plagued older methods. When antibody-modified nanowires were tested against cultured breast cancer cells, they achieved 90% capture efficiency for CD9-positive EVs, compared to just 65% for nanowires without antibodies.
The real proof came when the team tested the device on blood serum from actual patients. Working with Yasuhide Inokuma at Hokkaido University and colleagues from other institutions, researchers isolated EVs using nanowires modified with antibodies targeting three ovarian cancer markers: CLDN3, FOLR1, and TROP2. They analyzed blood from six patients with high-grade serous ovarian carcinoma—an aggressive subtype—and six noncancer individuals. The captured EVs retained their surface proteins and internal microRNAs intact, revealing a landscape of genetic differences between cancer and healthy patients. Across the three antibody types, researchers identified 126 microRNAs shared by ovarian cancer, plus unique signatures: 40 for CLDN3, 37 for FOLR1, and 45 for TROP2. These distinct fingerprints suggest that different tumor cells broadcast different molecular messages, opening doors to more granular diagnosis.
"We developed a nanowire microfluidic device capable of selectively capturing cancer-associated EVs with high efficiency while suppressing nonspecific adsorption through simple chemical modification," Yasui said in a statement about the work, published in the journal Device. The findings signal a shift toward rapid, specific cancer screening that requires minimal harm to patients. Kunanon Chattrairat, assistant professor and corresponding author, said the team plans to compare the technology against existing clinical methods and expand its use to detect other EV subtypes, with an ultimate goal of bringing this approach into clinical practice for noninvasive, early diagnosis across multiple cancer types.